Erschienen in:
27.05.2020 | Atrial Fibrillation
Efficacy and complications of cavo-tricuspid isthmus-dependent atrial flutter ablation in patients with and without structural heart disease: results from the German Ablation Registry
verfasst von:
Dirk G. Dechering, Bernd-Dieter Gonska, Johannes Brachmann, Thorsten Lewalter, Karl-Heinz Kuck, Dietrich Andresen, Stephan Willems, Stefan G. Spitzer, Florian Straube, Burghard Schumacher, Matthias Hochadel, Jochen Senges, Lars Eckardt
Erschienen in:
Journal of Interventional Cardiac Electrophysiology
|
Ausgabe 1/2021
Einloggen, um Zugang zu erhalten
Abstract
Background
The impact of structural heart disease (SHD) on safety and efficacy of catheter ablation of cavo-tricuspid isthmus-dependent atrial flutter (AFLU) is unclear. In addition, recent data suggest a higher complication rate of AFLU ablation compared to the more complex atrial fibrillation (AF) ablation procedure.
Methods and results
Within our prospective multicenter registry, 3526 consecutive patients underwent AFLU ablation at 49 German electrophysiological centers from 2007 to 2010. For the present analysis, the patients were divided into a group with SHD (n = 2164 [61.4%]; median age 69 years; 78.5% male) and a group without SHD (n = 1362 [38.6%]; 65 years; 70.3% male). In our study, SHD mainly encompasses coronary artery disease (52.6%), left ventricular ejection fraction ≤ 50% (47.6%), and hypertensive heart disease (28.0%). The primary ablation success (97%) and the incidence of major (0.2%) or moderate (1.2%) complications did not differ significantly between the two groups (P = 1.0 and 0.87, respectively). Vascular access site complications (0.6%), AV block III° (0.2%), and bleeding (≥ BARC II: 0.2%) were most common. After a median 562 days of follow-up, we observed a 2.92-fold higher one-year mortality (P < 0.0001) in patients with SHD. Patients’ satisfaction with the ablation therapy (72.0% satisfied) was close to the overall subjective tachyarrhythmia-free rate (70.7%).
Conclusions
The present analysis demonstrates that ablation of cavo-tricuspid isthmus dependent AFLU in patients with SHD has a comparable, excellent risk-benefit profile in our large “real-world” registry. Mortality rates expectedly are higher in patients with SHD and AFLU compared to patients without SHD.